Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Total Inventories : $34.0 Mil (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Ultragenyx Pharmaceutical Total Inventories?

Ultragenyx Pharmaceutical's total inventories for the quarter that ended in Dec. 2023 was $34.0 Mil. Ultragenyx Pharmaceutical's average total inventories from the quarter that ended in Sep. 2023 to the quarter that ended in Dec. 2023 was $32.9 Mil.

In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Ultragenyx Pharmaceutical's Net-Net Working Capital per share for the quarter that ended in Dec. 2023 was $-6.88.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Ultragenyx Pharmaceutical's Days Inventory for the three months ended in Dec. 2023 was 249.01.

Inventory Turnover measures how fast the company turns over its inventory within a year. Ultragenyx Pharmaceutical's Inventory Turnover for the quarter that ended in Dec. 2023 was 0.37.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ultragenyx Pharmaceutical's Inventory-to-Revenue for the quarter that ended in Dec. 2023 was 0.26.

Ultragenyx Pharmaceutical Total Inventories Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Total Inventories can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Total Inventories Chart

Ultragenyx Pharmaceutical Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Inventories

Get a 7-Day Free Trial

11.55

13.05

16.23

26.77

33.97

Ultragenyx Pharmaceutical Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Inventories	Get a 7-Day Free Trial															26.77	26.62	28.26	31.80	33.97

Ultragenyx Pharmaceutical Total Inventories Calculation

Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.

Ultragenyx Pharmaceutical (NAS:RARE) Total Inventories Explanation

Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.

1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.

Ultragenyx Pharmaceutical's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2023 is

	Net-Net Working Capital Per Share (Q: Dec. 2023 )
=	(Cash And Cash Equivalents	+	0.75 * Accounts Receivable	+	0.5 * Total Inventories	-	Total Liabilities
-	Preferred Stock	-	Minority Interest)	/	Shares Outstanding (EOP)
=	(577.209	+	0.75 * 73.39	+	0.5 * 33.969	-	1215.599
-	0	-	0)	/	82.3156
=	-6.88

2. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Ultragenyx Pharmaceutical's Days Inventory for the three months ended in Dec. 2023 is calculated as:

Days Inventory	=	Average Total Inventories (Q: Dec. 2023 )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
	=	32.8855	/	12.051	*	365 / 4
	=	249.01

3. Inventory Turnover measures how fast the company turns over its inventory within a year.

Ultragenyx Pharmaceutical's Inventory Turnover for the quarter that ended in Dec. 2023 is calculated as

Inventory Turnover	=	Cost of Goods Sold (Q: Dec. 2023 )	/	Average Total Inventories (Q: Dec. 2023 )
	=	12.051	/	32.8855
	=	0.37

4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ultragenyx Pharmaceutical's Inventory to Revenue for the quarter that ended in Dec. 2023 is calculated as

Inventory-to-Revenue	=	Average Total Inventories (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	32.8855	/	127.392
	=	0.26

Be Aware

Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.

When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.

Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.

Ultragenyx Pharmaceutical Total Inventories Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Total Inventories provided by GuruFocus.com. Please click on the following links to see related term pages.

Ultragenyx Pharmaceutical (Ultragenyx Pharmaceutical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (NAS:RARE) » Definitions » Total Inventories

Comparable Companies

Traded in Other Exchanges

RARE:Mexico UP0:Germany

Address

60 Leveroni Court, Novato, CA, USA, 94949

Website

https://www.ultragenyx.com

Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Executives

Emil D Kakkis	director, 10 percent owner, officer: President & CEO	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Thomas Richard Kassberg	officer: CBO & Senior Vice President	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Howard Horn	officer: Chief Financial Officer	C/O VIR BIOTECHNOLOGY, INC., 499 ILLINOIS STREET, SUITE 500, SAN FRANCISCO CA 94158
Theodore Alan Huizenga	officer: Controller and PAO	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Erik Harris	officer: EVP & Chief Commercial Officer	60 LEVERONI COURT, NOVATO CA 94949
Sanders Corazon (corsee) D.	director	C/O MOLECULAR TEMPLATES, INC., 9301 AMBERGLEN BLVD, SUITE 100, AUSTIN VI 78729
John Richard Pinion	officer: See Remarks	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Karah Herdman Parschauer	officer: EVP and General Counsel	60 LEVERONI COURT, NOVATO CA 94949
Eric Crombez	officer: EVP and Chief Medical Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Dennis Karl Huang	officer: SVP and Chief Tech Ops Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Camille L Bedrosian	officer: EVP and Chief Medical Officer	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Mardi Dier	officer: CFO & Executive Vice President	C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Amrit Ray	director	60 LEVERONI COURT, NOVATO CA 94949
William Aliski	director	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949
Shalini Sharp	officer: CFO & Senior Vice President	C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949